The NIH Clinical Center

A teen’s participation in clinical trials inspires a career in science

Mar 13, 2017

Nathan Porter, a 16-year-old student with a rare disease called multiple endocrine neoplasia, discussed his experience with the condition with The Daily Times of Blount County, Tennesse, for February’s Rare Disease Day. When first diagnosed with the disease at age 10, he says he thought “Why me?” However, in eighth grade, when the condition led him to participate in clinical trials at the NIH Clinical Research Center, he discovered his passion for science and has since applied for a summer internship at NIH. “Dealing with nurses and doctors of this degree really led me to my passion in the sciences and psychology and genetics, which is what I want to go into with my life,” he says. “My main passion is genetics, and what I would like to do is look at genetic cancers, go in there and see what exactly causes them to be passed down and look at how they get turned on.”  Learn more...

Safety and tolerability of combination therapy vs. standard treatment alone for patients with previously treated non-small cell lung cancer

Mar 3, 2017

Dr. James Gulley is leading a team to test the safety and tolerability of the combination of nivolumab and CV301 to see if it can improve the survival for patientis with metastatic non-small cell lung cancer.  Learn more...

Safety and tolerability of combination therapy vs. standard treatment alone for patients with previously treated non-small cell lung cancer
thyroid:  right lobe, isthmus, left lobe

A phase II study tests a new drug for patients with advanced thyroid cancer

Jan 24, 2017

A phase II trial of CUDC-907, a new drug that may be able to shrink thyroid tumors that have spread or gotten worse, is being tested in metastatic or advanced thyroid cancer.  Currently, there is no standard or effective treatment for the most aggressive types of thyroid cancer such as anaplastic and poorly differentiated thyroid cancer.  Learn more...

A phase II study tests a new drug for patients with advanced thyroid cancer

New study tests the safety and efficacy of combination therapy in adults with astrocytoma and glioblastoma

Dec 2, 2016

A two-part clinical trial of a multikinase inhibitor plus chemotherapy in patients with two types of brain tumors is enrolling in Bethesda, MD. The study will be open to patients with anaplastic astrocytoma, an uncommon malignant brain tumor that develops from star-shaped brain cells called astrocytes and glioblastoma, the most common and aggressive form of astrocytoma. Learn more...

New study tests the safety and efficacy of combination therapy in adults with astrocytoma and glioblastoma

New clinical trial tests safety and efficacy of combination therapy in ovarian cancer and other women's malignancies

Nov 9, 2016

The Center for Cancer Research has opened a new clinical trial in ovarian cancer that will test the safety and efficacy a therapy combining two drugs.   The phase I trial will test a combination therapy for ovarian, fallopian tube, and peritoneal cancers and is enrolling patients at the NIH Clinical Center. Learn more...

 

New clinical trial tests safety and efficacy of combination therapy in ovarian cancer and other women's malignancies

Fighting liver cancer with combination immunotherapies

Oct 21, 2016

A new clinical trial testing the effectiveness of immunotherapy treatment combinations against liver cancer is enrolling patients at the NIH Clinical Center in Bethesda, Maryland. Individually, immunotherapy drugs harness the power of the human immune system to better identify and kill cancer cells. Now, researchers at the NIH’s Center for Cancer Research have begun to find evidence that the drugs may work far more effectively when taken in combination with other therapies and with each other than when taken alone.

Fighting liver cancer with combination immunotherapies

Pages